Riccardo Autorino, MD, PhD, FEBU, presented “Cytoreductive Surgery in the Era of Targeted Therapy for Kidney Cancer: If Yes, When?” during the Jackson Hole Seminars on February 7, 2018 in Jackson Hole, Wyoming.
How to cite: Autorino, Riccardo. “Cytoreductive Surgery in the Era of Targeted Therapy for Kidney Cancer: If Yes, When?” February 7, 2018. Accessed Dec 2025. https://grandroundsinurology.com/Cytoreductive-Surgery-in-the-Era-of-Targeted-Therapy/
Cytoreductive Surgery in the Era of Targeted Therapy for Kidney Cancer: If Yes, When?
Summary:
Riccardo Autorino MD, PhD, FEBU, discusses the decline in using cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) due to the shift toward targeted therapy in urological practice. He explains the rationale behind CN, its drawbacks, and individual scenarios in which it could provide a benefit, as opposed to targeted therapy and nephron-sparing surgery (NSS). Furthermore, he presents the current therapeutic algorithm for patient selection in these treatment options.
ABOUT THE AUTHOR
Riccardo Autorino, MD, PhD, FEBU, is the Director of Clinical Outcomes Research for the Glickman Urological and Kidney Institute at the Cleveland Clinic in Cleveland, Ohio.His main clinical interest is the minimally-invasive treatment of urologic cancers and benign urologic diseases using robotic-assisted surgery.
